CA2024631A1 - Double-coated granules of disodium pamidronate - Google Patents

Double-coated granules of disodium pamidronate

Info

Publication number
CA2024631A1
CA2024631A1 CA2024631A CA2024631A CA2024631A1 CA 2024631 A1 CA2024631 A1 CA 2024631A1 CA 2024631 A CA2024631 A CA 2024631A CA 2024631 A CA2024631 A CA 2024631A CA 2024631 A1 CA2024631 A1 CA 2024631A1
Authority
CA
Canada
Prior art keywords
double
coated granules
disodium pamidronate
capsules
granules
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2024631A
Other languages
French (fr)
Other versions
CA2024631C (en
Inventor
Dagmar Wirth
Christian Bucher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Ciba Geigy AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy AG filed Critical Ciba Geigy AG
Publication of CA2024631A1 publication Critical patent/CA2024631A1/en
Application granted granted Critical
Publication of CA2024631C publication Critical patent/CA2024631C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The invention relates to an advantageous oral administration form for disodium pamidronate in capsules. These capsules are filled with double-coated granules. The inner coating is hydrophilic and elastic, and the outer coating is gastric juice-resistant and intestinal juice-soluble. The granules are distinguished by good gastric compatibility.
CA002024631A 1989-09-07 1990-09-05 Double-coated granules of disodium pamidronate Expired - Lifetime CA2024631C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH3245/89-3 1989-09-07
CH324589 1989-09-07

Publications (2)

Publication Number Publication Date
CA2024631A1 true CA2024631A1 (en) 1991-03-08
CA2024631C CA2024631C (en) 2000-11-21

Family

ID=4251793

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002024631A Expired - Lifetime CA2024631C (en) 1989-09-07 1990-09-05 Double-coated granules of disodium pamidronate

Country Status (21)

Country Link
US (1) US5096717A (en)
EP (1) EP0421921B1 (en)
JP (1) JP3009713B2 (en)
KR (1) KR910005852A (en)
AT (1) ATE104856T1 (en)
AU (1) AU623036B2 (en)
CA (1) CA2024631C (en)
DD (1) DD298049A5 (en)
DE (1) DE59005517D1 (en)
DK (1) DK0421921T3 (en)
ES (1) ES2052228T3 (en)
FI (1) FI93169C (en)
HU (1) HU207447B (en)
IE (1) IE63668B1 (en)
IL (1) IL95558A (en)
MX (1) MX22254A (en)
NO (1) NO176646C (en)
NZ (1) NZ235187A (en)
PH (1) PH27186A (en)
PT (1) PT95209B (en)
ZA (1) ZA907100B (en)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0520119A1 (en) * 1991-06-17 1992-12-30 Spirig Ag Pharmazeutische Präparate New oral diclofenac composition
US6764697B1 (en) 1991-06-27 2004-07-20 Alza Corporation System for delaying drug delivery up to seven hours
RU2113220C1 (en) * 1991-07-24 1998-06-20 Энзакор Пропертиз Лимитед Composition, method of enteric infection treatment, method of nonspecific stimulation of immune system, method of delivery of biologically active material in intestine upper regions
KR100274734B1 (en) * 1991-11-22 2000-12-15 제이코버스 코넬리스 레이서 Risedronate delayed-release compositions
EP0550385A1 (en) * 1991-12-19 1993-07-07 Ciba-Geigy Ag Oral pharmaceutical compositions containing derivatives of methane-diphosphonic acid and 18-crown-6 ethers
US5472712A (en) * 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5681585A (en) 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US7070806B2 (en) * 1992-01-27 2006-07-04 Purdue Pharma Lp Controlled release formulations coated with aqueous dispersions of acrylic polymers
FR2687291B1 (en) * 1992-02-17 1994-06-03 Sfbd Vivis SPORTS FOOD AND MANUFACTURING METHOD THEREOF.
TW237386B (en) 1992-04-15 1995-01-01 Ciba Geigy
US5286495A (en) * 1992-05-11 1994-02-15 University Of Florida Process for microencapsulating cells
IT1260505B (en) * 1992-06-01 1996-04-09 Poli Ind Chimica Spa ORAL PHARMACEUTICAL SYSTEMS WITH DELAYED DELIVERY FOR THE SPECIFIC RELEASE IN THE COLON
DE4236090C1 (en) * 1992-10-26 1994-01-05 Asta Medica Arzneimittel Pharmaceutical preparation for fluoride ion supply
US5993860A (en) * 1993-06-17 1999-11-30 Venture Lending NSADI delivery employing a powdered hydrocolloid gum obtainable from higher plants
US5431920A (en) * 1993-09-21 1995-07-11 Merck Frosst, Canada, Inc. Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents
TW390813B (en) * 1994-04-29 2000-05-21 Merck & Co Inc Wet granulation formulation for bisphosphonic acids
US20010007863A1 (en) 1998-06-18 2001-07-12 Merck & Co., Inc. Wet granulation formulation for bisphosphonic acids
US5766623A (en) * 1996-03-25 1998-06-16 State Of Oregon Acting By And Through The Oregon State Board Of Higher Education On Behalf Of Oregon State University Compactable self-sealing drug delivery agents
DE19637082A1 (en) * 1996-09-12 1998-03-19 Boehringer Mannheim Gmbh Rapidly disintegrating pellets
US5788987A (en) * 1997-01-29 1998-08-04 Poli Industria Chimica Spa Methods for treating early morning pathologies
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
NZ503946A (en) * 1997-06-11 2003-02-28 Procter & Gamble Oral dosage form in an oval or caplet shape for administration of bisphosphonates and other known medicaments
WO1999001111A1 (en) 1997-07-02 1999-01-14 Euro-Celtique, S.A. Stabilized sustained release tramadol formulations
US20020035071A1 (en) * 1997-07-08 2002-03-21 Josef Pitha Mimicking the metabolic effects of caloric restriction by administration of glucose antimetabolites
US20060116330A1 (en) * 1997-07-08 2006-06-01 The Iams Company Methods of mimicking the metabolic effects of caloric restriction by administration of mannoheptulose
US8563522B2 (en) * 1997-07-08 2013-10-22 The Iams Company Method of maintaining and/or attenuating a decline in quality of life
US6197331B1 (en) 1997-07-24 2001-03-06 Perio Products Ltd. Pharmaceutical oral patch for controlled release of pharmaceutical agents in the oral cavity
DE19732903A1 (en) 1997-07-30 1999-02-04 Falk Pharma Gmbh Pellet formulation for the treatment of the intestinal tract
US7008645B2 (en) * 1998-07-14 2006-03-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method of inhibiting restenosis using bisphosphonates
US6984400B2 (en) * 1998-07-14 2006-01-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method of treating restenosis using bisphosphonate nanoparticles
IL125336A0 (en) 1998-07-14 1999-03-12 Yissum Res Dev Co Compositions for inhibition and treatment of restinosis
US6794536B1 (en) 1998-12-10 2004-09-21 Aesqen, Inc. Method for preparation of disodium pamidronate
US6160165A (en) 1998-12-10 2000-12-12 Aesgen, Inc. Method for preparation of disodium pamidronate
US6245913B1 (en) 1999-06-30 2001-06-12 Wockhardt Europe Limited Synthetic procedure for 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methylthio]-IH-benzimidazole hydrochloride and its conversion to omeprazole
AR021347A1 (en) 1999-10-20 2002-07-17 Cipla Ltd A PHARMACEUTICAL COMPOSITION CONTAINING SISPHOSPHONIC ACID (S) OR SALT (S) OF THE SAME AND A PREPARATION PROCESS OF THE SAME
AU2127200A (en) * 1999-11-02 2001-05-14 Cipla Limited A pharmaceutical composition containing bisphosphonic acid(s) or salt(s) thereofand a process of preparing thereof
PL196485B1 (en) * 2000-05-11 2008-01-31 Inst Farmaceutyczny Solid oral pharmacological composition containing a derivative of bisphosphonic acid and method of obtaining same
MXPA03008293A (en) * 2001-03-13 2003-12-11 Penwest Pharmaceuticals Co Chronotherapeutic dosage forms.
CA2372450A1 (en) * 2001-05-10 2001-09-19 Pharmaceutical Partners Of Canada Inc. Liquid injectable formulation of disodium pamidronate
US8168170B2 (en) * 2002-10-03 2012-05-01 The Procter And Gamble Company Compositions having an inner core and at least three surrounding layers
US20040138180A1 (en) * 2002-10-03 2004-07-15 Barr Laboratories, Inc. Bisphosphonate composition and process for the preparation thereof
US20060051407A1 (en) * 2003-06-27 2006-03-09 Yoram Richter Method of treating ischemia-reperfusion injury
US10517883B2 (en) 2003-06-27 2019-12-31 Zuli Holdings Ltd. Method of treating acute myocardial infarction
MXPA06003101A (en) * 2003-09-19 2006-06-20 Penwest Pharmaceuticals Co Chronotherapeutic dosage forms.
US8389008B2 (en) * 2003-09-19 2013-03-05 Penwest Pharmaceuticals Co. Delayed release dosage forms
US8894991B2 (en) * 2003-12-19 2014-11-25 The Iams Company Canine probiotic Lactobacilli
US8877178B2 (en) * 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
US20050152884A1 (en) * 2003-12-19 2005-07-14 The Procter & Gamble Company Canine probiotic Bifidobacteria globosum
US20050158294A1 (en) * 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
US7785635B1 (en) 2003-12-19 2010-08-31 The Procter & Gamble Company Methods of use of probiotic lactobacilli for companion animals
SI21637A (en) * 2003-12-23 2005-06-30 LEK farmacevtska dru�ba d.d. Pharmaceutical form with controlled release
WO2006018033A1 (en) * 2004-08-20 2006-02-23 Mepha Ag Formulations of bisphosphonates
AU2006253007B2 (en) * 2005-05-31 2012-12-20 Alimentary Health Ltd Feline probiotic Bifidobacteria
DK1880001T3 (en) * 2005-05-31 2011-09-12 Iams Company Feline probiotic lactobacilli
US7473684B2 (en) * 2005-09-16 2009-01-06 Selamine Limited Bisphosphonate formulation
GB0624084D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril amino acid salts
GB0624087D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril combination salt
GB0624090D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril amine salts
JP5799299B2 (en) 2007-02-01 2015-10-21 ザ・アイムス・カンパニーThe Iams Company Method for reducing inflammation and stress in mammals using glucose antimetabolite, avocado or avocado extract
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
DE102009033621A1 (en) 2009-07-17 2011-01-20 Add Technologies Ltd. Separating layers for pharmaceutical preparations for preventing interactions between drugs and pharmaceutical-technological excipients
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
US8663671B2 (en) * 2009-11-05 2014-03-04 Philip Morris Usa Inc. Methods and compositions for producing hydrogel capsules coated for low permeability and physical integrity
US9993427B2 (en) 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture
CA2936746C (en) 2014-10-31 2017-06-27 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7813246L (en) * 1978-12-22 1980-06-23 Haessle Ab FIXED PHARMACEUTICAL PREPARATION INCLUDING BODIES WITH MULTIPLE LAYERS
PH18946A (en) * 1983-04-21 1985-11-14 Elan Corp Plc Controlled absorption pharmaceutical composition
US4639338A (en) * 1984-08-06 1987-01-27 Ciba-Geigy Corporation Preparation of crystalline disodium 3-amino-1-hydroxypropane-1,1-diphosphonate pentahydrate
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
GB2189699A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
US4983401A (en) * 1989-05-22 1991-01-08 Kinaform Technology, Inc. Sustained release pharmaceutical preparations having pH controlled membrane coatings

Also Published As

Publication number Publication date
DD298049A5 (en) 1992-02-06
ATE104856T1 (en) 1994-05-15
HU207447B (en) 1993-04-28
ES2052228T3 (en) 1994-07-01
NO176646C (en) 1995-05-10
FI93169C (en) 1995-03-10
NO176646B (en) 1995-01-30
AU623036B2 (en) 1992-04-30
DK0421921T3 (en) 1994-05-30
IE63668B1 (en) 1995-05-31
NZ235187A (en) 1992-03-26
EP0421921A1 (en) 1991-04-10
HUT59008A (en) 1992-04-28
EP0421921B1 (en) 1994-04-27
IL95558A0 (en) 1991-06-30
NO903892D0 (en) 1990-09-06
IL95558A (en) 1995-08-31
CA2024631C (en) 2000-11-21
PT95209A (en) 1991-05-22
ZA907100B (en) 1991-05-29
NO903892L (en) 1991-03-08
PT95209B (en) 1998-06-30
JP3009713B2 (en) 2000-02-14
HU905812D0 (en) 1991-03-28
MX22254A (en) 1993-12-01
IE903239A1 (en) 1991-03-13
KR910005852A (en) 1991-04-27
FI904341A0 (en) 1990-09-03
DE59005517D1 (en) 1994-06-01
US5096717A (en) 1992-03-17
JPH0399016A (en) 1991-04-24
AU6228390A (en) 1991-03-14
FI93169B (en) 1994-11-30
PH27186A (en) 1993-04-16

Similar Documents

Publication Publication Date Title
CA2024631A1 (en) Double-coated granules of disodium pamidronate
CA2041260A1 (en) Ultrasonic contrast agents, processes for their preparation and the use thereof as diagnostic and therapeutic agents
MY103525A (en) Pharmaceutical composition comprising cefuroxime axetil
AU3811089A (en) Chewable, edible soft gelatin capsule
IE811911L (en) Suspension-yielding powder
AU2219988A (en) Drug capsule
AU1578688A (en) Pharmaceutical composition, for oral administration, designed to attenuate the effects of beta-lactamines
EP0357793A4 (en) Suspended-release preparation prepared by using alginic acid
ATE124255T1 (en) ORAL FORMULATIONS CONTAINING POLYPEPTIDES THAT DISBAVE IN THE LARGE INTESTINE.
AU650261B2 (en) Derivatives of glycinamide, their preparation and medicaments containing them
CA2038744A1 (en) Pharmaceutical composition containing slightly water-soluble drug
NO883122D0 (en) PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE ARYLAMIDE DERIVATIVES.
GB1515241A (en) Beta-lactam antibiotics
CA2033418A1 (en) Pharmaceutical preparation for oral administration in fluid form
AU563822B2 (en) Pharmaceutical composition of piroxicam and 5'-guanylic acid or n-acetyl-l-methionine
NO883986D0 (en) PROCEDURE FOR THE PREPARATION OF N- (SUBSTITUTED ALKYLIDE) -1,2,3,4-TETRAHYDRO-9 ACRIDINAMINES AND USE THEREOF AS MEDICINES.
CA2341366A1 (en) Micronised pharmaceutical compositions
WO1998036732A3 (en) Combination preparation for orally administered antibiotics
NO891574L (en) PROCEDURE FOR THE PREPARATION OF PHARMACEUTICAL USES.
NO860091L (en) PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE 12-AMINO-PYRIDAZINO (4 [, 5 [: 3,4) PYRROLO (2,1-A) ISOKINOLIN DERIVATIVES.
CA2077762A1 (en) New use of bambuterol
GB9420748D0 (en) 1,5 benzodiazepine derivatives
NO901893D0 (en) PROCEDURE FOR THE PREPARATION OF PENEM CONNECTIONS.
NO170541C (en) ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE 1,5-BENZOTIAZEPINE DERIVATIVES
IT8920927A0 (en) PROCEDURES FOR THE PREPARATION OF PROSTANOIC COMPOUNDS WITH ANTIPLATELET AGGREGATION, ANTITHROMBOTIC ACTIVITY, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry